Eli Lilly is dropping the development of three therapies that did not meet expectations, including an acquired gene therapy.

The Medicines and Healthcare products Regulatory Agency (MHRA) is formalising its review process around in vitro diagnostics ...

SEQSTER has announced the expansion of its partnership with Praxis Precision Medicines to expedite clinical trials in CNS ...

CalciMedica will now evaluate how it can safely progress Auxora’s development in AKI, while finalising plans for a Phase III ...

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in ...

Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap its development.

Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.

William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.

The trial aims to assess biological and clinical activity of TTX-MC138 in patients with MRD. Credit: Pickadook / Shutterstock.com. A partnership comprising TransCode Therapeutics and Quantum Leap ...

AFTX-201 uses Affinia’s engineered capsid for efficient cardiac delivery at doses lower than conventional AAV9 or AAVrh74. Credit: Komsan Loonprom / Shutterstock.com. Affinia Therapeutics has received ...